TH1/17 hybrid CD4+ cells in bronchial alveolar lavage fluid from leukemia patients with checkpoint inhibitor-induced pneumonitis.
Kim S, Shannon V, Sheshadri A, Kantarjian H, Garcia-Manero G, Im J, Ravandi F, Naing A, Futreal A, Daver N. TH1/17 hybrid CD4+ cells in bronchial alveolar lavage fluid from leukemia patients with checkpoint inhibitor-induced pneumonitis. Journal Of Clinical Oncology 2018, 36: 204-204. DOI: 10.1200/jco.2018.36.5_suppl.204.Peer-Reviewed Original ResearchAcute myeloid leukemiaBronchial alveolar lavageMyelodysplastic syndrome patientsCD4+ cellsImmune related adverse eventsMyelodysplastic syndromeCell subsetsImmune checkpoint inhibitor (ICI)-based therapyPneumonitis groupCD4+ cell subsetsAnalyzed BAL fluidBronchial alveolar lavage fluidRegulatory T cellsRelated adverse eventsAlveolar lavage fluidLineage specific markersPD-1BAL fluidMyeloid leukemiaT cellsLeukemia patientsLung inflammationRisk stratificationAdverse eventsLavage fluid